Teva expands European biosimilars push with AHZANTIVE launch for eye disease treatment

Teva said the launch strengthens its biosimilars strategy and expands access to biologic medicines across Europe

Biocon Biologics secures market entry date for Yesafili in US

YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions

Biocon Biologics’ receives FDA approval for Biosimilar Aflibercept for Yesafili

The approval of YESAFILI marks Biocon Biologics’ expansion into the ophthalmology therapeutic area in the United States

Biocon Biologics receives MHRA, UK Approval for Biosimilar Aflibercept ‘Yesafili’

Yesafili, received marketing authorization approval from the European Commission for the European Union

Biocon Biologics receives European Commission approval for biosimilar of Aflibercept ‘Yesafili’

The centralized marketing authorization granted by the EC is valid in all EU Member States as well as in the European Economic Area (EEA) countries Iceland, Liechtenstein and Norway

Biocon Biologics gets EMA’s positive opinion for an ophthalmology product

50% of the world's population expected to be myopic by 2050

Researchers have found out that myopia often leads to an abnormal increase in axial length. When the axial length grows to more than 25mm, especially with age, problems like cataracts or glaucoma can appear